Candida auris guidance update: summary of changes [withdrawn]
Updated 2 April 2025
© Crown copyright 2025
This publication is licensed under the terms of the Open 바카라 사이트 Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at /government/consultations/candida-auris-update-to-management-guidance/candida-auris-guidance-update-summary-of-changes
This consultation is now closed. Feedback has been incorporated into the updated Candidozyma auris (formerly Candida auris): guidance for acute healthcare settings.
The Candida auris guidance was first published on 27 June 2016 and last updated on 11 August 2017.
Here is a summary of the changes:
- updated data on laboratory reporting to the Second Generation Surveillance System (SGSS) provided up until 2021 in the introduction; 2022 data will feature in the forthcoming ESPAUR report
- new data from one secondary care provider that offers a screening programme to international patients within the independent sector in the introduction
- investigation in laboratories (section 2) expanded to include sub-sections addressing culture, biochemical, and molecular identification in greater detail; a new chromogenic agar, CHROMagarâ„¢ Candida Plus, is suggested as a screening tool for Candida auris
- expanded recommendations for contact screening under 3.2 Screening policies:
- if detected in an intensive care or other vulnerable patient setting, a one-off point prevalence survey is now recommended (previously recommended to screen close contacts)
- if detected on a general ward, screen close contacts and where there is evidence of ongoing transmission, screen the entire ward area
- greater detail provided on the ability of Candida auris to contaminate and persist in the healthcare environment within the infection, prevention, and control section 바카라 사이트“ for example, time to colonisation following exposure, the range of equipment from which Candida auris has been detected during outbreaks and survival times on surfaces
- additional recommendations for reusable patient care equipment, patient movement, and surgical procedures for those colonised or infected with Candida auris within the infection, prevention, and control section